In the AUGUSTUS trial, DAT consisting of apixaban and a P2Y12 inhibitor was investigated in comparison to a combination of VKA and a P2Y12 inhibitor or TAT (in addition to aspirin) in 4614 patients with atrial fibrillation who had recent ACS (37.3%) or PCI. The gene discussed is P2RY12; the disease is atrial fibrillation.